The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.
Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrolysis contributes to bleeding.
A patient-centered education bundle intervention can reduce nonadministration of venous thromboembolism prophylaxis.
Patients with splanchnic vein thrombosis may be at an increased risk for bleeding and arterial cardiovascular events for years after diagnosis.
Venous thromboembolism recurrence risk may not be any higher in older patients than in younger patients.
Patients with VTE with moderate to severe thrombocytopenia at baseline were associated with increased risk for major bleeding events and all-cause mortality.
A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.
More pronounced differences in venous thromboembolism and ischemic stroke in individuals who initiated hormone treatment during follow-up.
Patients treated for acute pulmonary embolism with direct oral anticoagulants at doses against manufacturer recommendations had a higher rate of major bleeding events.
Greater difference in physical decline for women specifically reporting pulmonary embolism.
